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Abstract
Background: Compelling evidence has implicated neuroinflammation in the pathogenesis of a number of
neurodegenerative conditions. Chronic activation of both astrocytes and microglia leads to excessive secretion of
proinflammatory molecules such as TNFα, IL-6 and IL-1β with potentially deleterious consequences for neuronal
viability. Many signaling pathways involving the mitogen-activated protein kinases (MAPKs), nuclear factor κB (NFκB)
complex and the Janus kinases (JAKs)/signal transducers and activators of transcription (STAT)-1 have been
implicated in the secretion of proinflammatory cytokines from glia. We sought to identify signaling kinases
responsible for cytokine production and to delineate the complex interactions which govern time-related responses
to lipopolysaccharide (LPS).
Methods: We examined the time-related changes in certain signaling events and the release of proinflammatory
cytokines from LPS-stimulated co-cultures of astrocytes and microglia isolated from neonatal rats.
Results: TNFα was detected in the supernatant approximately 1 to 2 hours after LPS treatment while IL-1β and IL-6
were detected after 2 to 3 and 4 to 6 hours, respectively. Interestingly, activation of NFκB signaling preceded
release of all cytokines while phosphorylation of STAT1 was evident only after 2 hours, indicating that activation of
JAK/STAT may be important in the up-regulation of IL-6 production. Additionally, incubation of glia with TNFα
induced both phosphorylation of JAK2 and STAT1 and the interaction of JAK2 with the TNFα receptor (TNFR1).
Co-treatment of glia with LPS and recombinant IL-6 protein attenuated the LPS-induced release of both TNFα and
IL-1β while potentiating the effect of LPS on suppressor of cytokine signaling (SOCS)3 expression and IL-10 release.
Conclusions: These data indicate that TNFα may regulate IL-6 production through activation of JAK/STAT signaling
and that the subsequent production of IL-6 may impact on the release of TNFα, IL-1β and IL-10.
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Background
Compelling evidence has implicated neuroinflammation
in the pathogenesis of a number of neurodegenerative
conditions. Inflammatory processes in the central ner-
vous system (CNS) are mediated by activated glial cells
that are capable of producing immunomodulatory mole-
cules, phagocytosing cellular debris and recruiting im-
mune cells from the periphery. Although activation of
glia is essential for the maintenance of neuronal function
following stress or insult, an uncontrolled response is
highly undesirable given the lack of regenerative capacity
of the brain.
Microglia are the resident macrophage-like cells of the
brain and, as such, play an important role in the main-
tenance of homeostasis and host cell defense and repair.
Astrocytes provide structural, metabolic and trophic
support for neurons [1] but they, like microglia, are im-
munocompetent cells capable of secreting inflammatory
mediators. Chronic activation of both cell types leads to
excessive secretion of proinflammatory molecules such
as TNFα, IL-6 and IL-1β, an effect that may have dele-
terious consequences for neuronal viability. Indeed
enhanced microglial activation, astrogliosis and up-
regulation of TNFα, IL-1β and IL-6 expression have
been reported in Alzheimer’s disease as well as
Parkinson’s disease [2-5].
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Microglia and macrophages release TNFα, IL-1β and
IL-6 upon activation with the bacterial endotoxin lipo-
polysaccharide (LPS) in vitro [6,7]. The release of these
cytokines is mediated by protein tyrosine kinases,
mitogen-activated protein kinases (MAPKs) and tran-
scription factors such as nuclear factor кB (NFкB) [8].
However, a specific involvement for each of these
kinases in the release of one or other of the cytokines
has been difficult to identify.
Type I and Type II cytokines recruit non-receptor
tyrosine kinases such as Janus kinases (JAKs) to initiate
signal transduction since they lack kinase domains.
Interaction of JAK proteins with receptors induces
autophosphorylation and causes JAKs to associate with,
and activate members of, the signal-transducers and
activators of transcription (STAT) which translocate to
the nucleus and up-regulate transcription of a number
of inflammatory genes [9]. In the present study, we
examined the activation of several signaling pathways
and the release of proinflammatory cytokines from co-
cultures of astrocytes and microglia isolated from neo-
natal rats in response to LPS. Using flow cytometry, we
established that co-cultures contained approximately
80% astrocytes and 16% microglia. Here we show the in-
volvement of JAK2/STAT1 signaling in mediating LPS-
induced activation of glia using SAR317461 (formerly
TG101209; Sanofi-Aventis, Cambridge, MA USA), a
novel specific inhibitor of JAK2.
Methods
Materials
LPS (Alexis Biochemicals, Exeter, UK), TNFα (R&D Sys-
tems, Abingdon, UK), IL-6 and non-target (NT) siRNA
(Invitrogen, Paisley, UK), recombinant IL-6 (R&D Sys-
tems), anti-IL-6 receptor and isotype (IgG2b) control
antibodies (Biolegend, San Diego, CA, USA), IL-1β Duo-
set ELISA kit (R&D Systems), IL-6 and TNFα ELISA kits
(BD Biosciences, Oxford, UK), anti-phospho-JAK2,
JAK2, anti-phospho-JAK1, anti-phospho-STAT1, STAT1,
anti-phospho-IκBα and anti-SOCS3 (Cell Signalling,
Danvers, MA, USA), anti-phospho-c-jun and anti-TNFα
receptor (TNFR1) (Santa Cruz Biotechnology, Heidel-
berg, Germany, and anti-actin (Sigma, Dorset, UK) were
all purchased commercially. SAR317461, a specific JAK2
inhibitor, was a gift from Sanofi-Aventis.
Primary mixed glial cultures
As astrocytes alone lack sufficient IL-6Rα subunits, and
require shedding of IL-6R to mediate IL-6 signaling [10],
mixed glial cultures were prepared from the cortices of
1 day old Wistar rats (Trinity College, Dublin, Ireland).
Cortical tissue was cross-chopped, incubated for 25 min-
utes at 37 °C in DMEM (Invitrogen) supplemented with
10% Foetal Bovine Serum (Invitrogen) and 50 U/ml
penicillin/streptomycin (Invitrogen) and plated (1 × 104/
cm2) as previously described [11]. Using flow cytometry,
we established that co-cultures contained approximately
80% astrocytes and 16% microglia. After 12 days in cul-
ture, cells were pre-treated with a JAK2 inhibitor,
SAR317461 (2 μM) for 20 minutes, after which cells
were treated with LPS (100 ng/ml) in the presence or
absence of SAR317461 for 0 to 24 h. Supernatants were
collected and the cells were harvested for analysis of
mRNA or lysed for analysis of protein expression.
For co-immunoprecipitation experiments, cells were
seeded in 25 cm2 flasks and, after 12 days in culture,
were treated with TNFα (5 ng/ml) for 0 to 40 minutes.
Cell lysates were harvested and the interaction between
TNFR1 and the phosphorylated form of JAK2 was
assessed by co-immunoprecipitation. To examine the ef-
fect of JAK2 inhibition on TNFα-induced changes, cells
were treated with TNFα in the presence or absence of
SAR317461. Cells and supernatants were harvested at 10
minutes and 6 h, respectively. MTS viability assay
(Promega, Southampton, UK) was performed on cells
that had been treated with TNFα (5 ng/ml) for up to
24 h.
In another set of experiments, the effect of IL-6 on
LPS treatment was assessed in a number of ways: cells
were treated with recombinant IL-6 or a neutralizing
antibody to the IL-6 receptor or the relevant isotype
control (IgG2b); or IL-6 release was inhibited through
knock down of the IL6 gene. Cells were co-incubated for
24 h in the presence or absence of LPS and recombinant
IL-6 (20 ng/ml), anti-IL-6 receptor antibody or the iso-
type control (IgG2b; 100 ng/ml), or either IL6 siRNA or
NT siRNA (50 nM). Supernatants and cells were har-
vested and assessed for cytokine concentration and
mRNA expression, respectively.
Analysis of IL-1β, IL-6, TNFα and IL-10 concentrations
Supernatant concentrations of IL-1β (R&D Systems), IL-
6 and TNFα (BD Biosciences) obtained from glial
cultures were measured using ELISA. Cytokine concen-
trations in the test samples were evaluated with refer-
ence to the standard curves prepared using recombinant
cytokines of a known concentration.
Analysis of proteins by western immunoblotting
Western blotting was performed as previously described
[12]. Cultured cells were harvested, homogenized in buf-
fer containing Tris–HCl (0.01 M) and ethylenediamine-
tetraacetic acid (EDTA) (1 mM), and protein (20 μg) was
boiled in gel-loading buffer and separated by 7 or 12%
sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis. For co-immunoprecipitation experiments,
lysates were harvested and immunoprecipitated using an
antibody raised against the TNFR1 prior to separation of
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proteins on 7% sodium dodecyl sulphate-polyacrylamide
gels. Proteins were transferred to nitrocellulose mem-
branes and incubated with antibodies diluted in 5% non-
fat dried milk in tris-buffered saline containing 0.05%
Tween-20 (TBS-T) against the following: β-actin
(1:5000), phospho-JAK2, phospho-STAT1, JAK2, STAT1,
phospho-c-jun, anti-SOCS3 and phospho-IκBα (1:1000)
for 16 h at 4 °C.
Membranes were incubated with horseradish
peroxidise-conjugated secondary antibodies (1:10,000 in
5% non-fat dried milk in TBS-T; Jackson ImmunoRe-
search, Suffolk, UK) and bands were visualised using
Supersignal West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL,USA). Images were captured using
a Fujifilm LAS-3000 (Brennan and Co, Dublin, Ireland).
Statistical analysis
Data were analysed using analysis of variance (ANOVA)
followed by Newmann Keul’s test or Student’s t-test for
independent means where appropriate to determine
which conditions were significantly different from each
other. All experiments were performed three times in
triplicate. Data are expressed as means ± SEM.
Results
LPS induces activation of JAK/STAT, MAPK and NFκB
signaling pathways and proinflammatory cytokine
secretion
The expression and release of cytokines were examined in
a time-dependent manner. Incubation of primary glia with
LPS (100 ng/ml) stimulated significant increases in TNFα
mRNA expression at 30 minutes (P< 0.05; ANOVA;
Figure 1A) and release of TNFα at 1 h (P< 0.05; see inset;
Student’s t-test for independent means; Figure 1B). IL-1β
mRNA expression was increased at 1 h (P< 0.01; Student’s
t-test for independent means; Figure 1C) and IL-1β release
was increased at 3 h (P< 0.05; ANOVA; Figure 1D).
Changes in IL-6 mRNA and release occurred later; IL-6
mRNA expression was significantly increased at 2 h
(P< 0.05; ANOVA; Figure 1E) whereas increased IL-6 re-
lease became evident only after 4 h (P< 0.001; ANOVA;
Figure 1F). Treatment of primary glia with LPS (100 ng/ml)
enhanced the expression of phosphorylated IκBα and c-jun
between 10 and 30 minutes while phosphorylation of JAK2
and STAT1 was not apparent until 120 minutes
(Figure 1G). No phosphorylation of JAK1 in response to
LPS was apparent at any time point examined (Figure 1H,
upper panel).
Inhibition of JAK2 attenuates the LPS-induced
phosphorylation of STAT1 and the release of
pro-inflammatory cytokines TNFα and IL-6
We used a specific JAK2 inhibitor, SAR317461, to evalu-
ate the role of JAK2 in modulating LPS-induced
changes. First, we confirmed that incubation of glia in
the presence of LPS for 2 h increased JAK2 (upper
panel; Figure 2A) and STAT1 (middle panel; Figure 2A)
phosphorylation. Interaction of JAK proteins with their
cognate receptors induces autophosphorylation of JAK.
Predictably, treatment of glia with LPS and the specific
JAK2 inhibitor, SAR317461, attenuated the LPS-induced
enhancement of phosphorylated JAK2 and STAT1
(Figure 2A). No effect of SAR317461 was observed on
the LPS-stimulated activation of NFкB signaling
(Figure 2B). Additionally, SAR317461 had no effect on
cell viability, even up to 5 μM concentration (data not
shown). LPS significantly increased release of TNFα
from glial cells at 6 h (P< 0.001; ANOVA; Figure 2C)
and this was significantly attenuated when cells were
incubated in the presence of SAR317461 (P< 0.01;
ANOVA; Figure 2C). While the LPS-stimulated release
of IL-1β at 6 h (P< 0.05; ANOVA; Figure 2D) was
enhanced when cells were co-treated with SAR317461
(P< 0.001; ANOVA; Figure 2D), the LPS-induced in-
crease in expression of IL-6 mRNA at 3 h (P< 0.001;
ANOVA; Figure 2E) and release of IL-6 at 6 h (P
< 0.001; ANOVA; Figure 2F) were significantly attenu-
ated when JAK2 was inhibited (P< 0.001; ANOVA;
Figure 2E,F).
JAK2 associates with the TNFR1 and induces release of IL-6
JAK/STAT signaling is usually associated with cytokine
receptors that lack intrinsic tyrosine kinase activity, and a
number of cytokines mediate their signals through associ-
ation with JAK2, including IL-6 and IL-12 [13,14]. The
data from this study indicate that IL-6 was not released
until 4 h after LPS treatment (Figure 1F), and IL-12 was
not detected before 9 h following LPS treatment of glial
cells (data not shown). In this study, the activation of
JAK2 coincided with significant release of TNFα and, con-
sequently, the effect of TNFα on JAK2 signaling was
investigated. Glial cells were treated with TNFα and the
interaction of TNFR1 and JAK2 was assessed by co-
immunoprecipitation. TNFα treatment of glial cells
enhanced the association between phosphorylated JAK2
and TNFR1 at 5 minutes (Figure 3A). Similarly, STAT1
phosphorylation was evident within 10 minutes of TNFα
treatment (Figure 3B), and the TNFα-induced expression
of phosphorylated JAK2 (Figure 3C, upper panel) and
STAT1 (Figure 3C, middle panel) were inhibited when
cells were co-incubated in the presence of SAR317461.
Since TNFα was capable of inducing JAK/STAT signaling,
we considered that the LPS-induced release of TNFα and
subsequent activation of JAK2 may trigger release of IL-6.
To assess this, glia were incubated with TNFα in the pres-
ence or absence of SAR317461 for 6 h. The data show that
TNFα significantly increased IL-6 release (P< 0.001;
ANOVA; Figure 3D) and that this effect was attenuated
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when cells were co-incubated with the JAK2 inhibitor
(P< 0.001; ANOVA; Figure 3D). To ensure that the con-
centration of TNFα used here was not toxic, cells were
incubated for up to 24 h with TNFα (5 ng/ml) and viability
assessed using an (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2 H-tetrazolium
(MTS) viability assay (Figure 3E). TNFα did not have any
adverse effect on cell viability under the conditions used
here (P< 0.05; Student’s t-test for independent means;
Figure 3E).
IL-6 modulates the LPS-stimulated release of IL-1β from glia
It has been reported that IL-6 can act as a switch be-
tween innate and adaptive immunity [15] and that it can
also act as an anti-inflammatory cytokine under certain
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Figure 1 LPS stimulates activation of JAK/STAT, c-jun and NFкB signaling pathways and release of proinflammatory cytokines from
glial cells. Stimulation of glial cells with LPS (100 ng/ml) enhanced the expression of TNFα mRNA at 30 minutes (A; *P< 0.05;ANOVA; n = 3),
release of TNFα at 1 h (B, see inset; *P< 0.05; Student t-test for independent means; n = 3), IL-1β mRNA expression at 1 h (C; **P< 0.01; ANOVA;
n = 3), IL-1β release at 3 h (D; *P< 0.05; ANOVA; n = 3), IL-6 mRNA expression at 2 h (E; *P< 0.05; ANOVA; n = 3) and IL-6 release at 4 h (F;
***P< 0.001; ANOVA; n = 3). Sample immunoblots (representative of three separate experiments) indicate that expression of phosphorylated-IκB,
-c-jun, -JAK2 and STAT1 were all enhanced in glial cells incubated with LPS for 10, 30, 60 and 120 minutes (G). Expression of phosphorylated JAK1
was unchanged in cells that were treated with LPS (H).
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between pro- and anti-inflammatory cytokines. We con-
sidered that IL-6 might impact on the LPS-induced re-
lease of IL-1β at later time-points and, to investigate
this, cells were incubated for 24 h with LPS in the pres-
ence or absence of recombinant IL-6. LPS significantly
increased the release of IL-1β (P< 0.001; ANOVA;
Figure 4A) and recombinant IL-6 partially attenuated its
release ( P< 0.05; ANOVA; Figure 4A). One mechanism
by which IL-6 might modulate IL-1β production is by
increasing expression of suppressor of cytokine signaling
(SOCS) proteins. Here we show that the LPS-associated
increase in SOCS3 expression, which was evident at 90
minutes, was enhanced by IL-6 (Figure 4B, upper panel).
A second possible mechanism by which IL-6 may
modulate IL-1β release is by increasing anti-
inflammatory cytokines such as IL-10. We demonstrate
that co-treatment of glial cells with recombinant IL-6
enhanced the LPS-induced release of IL-10 at 24 h
(P< 0.05; ANOVA; Figure 4C).
To further investigate the effect of IL-6 on glial cell
production of IL-1β, IL-6 signaling was down-regulated
by incubating cells with LPS in the presence or absence
of a neutralizing antibody to the IL-6 receptor or an iso-
type (IgG) control (Figure 4D,E). The LPS-stimulated
production of IL-1β (P< 0.001; ANOVA; Figure 4D) was
enhanced when cells were co-treated with a neutralizing
- + - +


































































Figure 2 Inhibition of JAK2 attenuates LPS-stimulated release of TNFα and IL-6 from glial cells. A sample immunoblot indicates that
expression of phosphorylated JAK2 and STAT1 were enhanced in glial cells treated with LPS (2 h; 100 ng/ml), and that this effect was attenuated
when cells were incubated in the presence of a specific JAK2 inhibitor, SAR317461 (2 μM) (A). Expression of phosphorylated IкBα was enhanced
in cells that were treated with LPS (B); however, co-incubation of cells with LPS and SAR317461 had no effect on the LPS-induced expression of
phosphorylated IкBα (B). The LPS-stimulated release of TNFα at 6 h (C; ***P< 0.001; ANOVA; n = 3) was attenuated when cells were co-incubated
with LPS and SAR317461 (++P< 0.01; ANOVA; n = 3), whereas inhibition of the LPS-induced expression of phospho-JAK2/STAT1 using SAR317461
enhanced the LPS-induced release of IL-1β at 9 h (D; +++P< 0.001; ANOVA; n = 3). The LPS-induced up-regulation of IL-6 mRNA (E; ***P< 0.001;
ANOVA; n = 3) was attenuated when cells were co-treated with SAR317461 (E; +++P< 0.001; ANOVA; n = 3) as was the release of IL-6
(F; +++P< 0.001; ANOVA; n = 3).
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antibody to the IL-6 receptor compared to treatment
with the IgG control antibody (P< 0.01; ANOVA;
Figure 4D), whereas the LPS-induced effect on IL-10
production ( P< 0.05; ANOVA; Figure 4E) was attenu-
ated ( P< 0.05; ANOVA; Figure 4F). Consistently, inhib-
ition of the LPS-induced release of IL-6 using siRNA
targeted to IL6 (Figure 4F,G) enhanced the LPS-induced
release of IL-1β (P< 0.05; ANOVA; Figure 4F).
Discussion
The purpose of the present study was to examine the
factors which impact on time-related release of inflam-
matory cytokines following LPS stimulation focusing, in
particular, on the role of the JAK2/STAT1 signaling
pathway. The data show that LPS-induced TNFα trig-
gers activation of JAK2/STAT1, and reveal a role for
JAK2 activation in the LPS-stimulated release of IL-6
which, in turn, modulates IL-1β production.
SAR317461, a small molecule inhibitor of JAK2 identified
by structure-based drug design [20], was used as it has been
shown to potently down-regulate expression of phosphory-
lated JAK2 and STAT1 without affecting expression of total
JAK2 and STAT1 in multiple myeloma cell lines [21]. Here
we show that SAR317461 potently inhibits phosphorylation
of JAK2 itself along with the JAK2 substrate STAT1 in
LPS-stimulated glial cells. A similar effect has been
reported in hematopoietic progenitor cells [22] and lung
cancer cells [23]. LPS did not affect phosphorylation of
JAK1 in glia, indicating a specific role for JAK2 in LPS-
stimulated changes.
A primary role for JAK2 was identified in the LPS-
stimulated release of IL-6, since co-treatment of glia with
LPS and SAR317461 attenuated IL-6 release. In agreement
with previous reports [15], the LPS-induced release of
TNFα from glia preceded release of IL-6, which became de-
tectable in supernatant after 4 hours. IL-6 lacks a trans-
membrane domain, and is transported to the plasma
membrane to enable constitutive release, consequently
intracellular IL-6 concentration is very low [24]. This sug-
gests that LPS-stimulated release of IL-6 occurs as a result
of enhanced transcription of IL-6, and this is consistent
with the observation that IL-6 mRNA was increased 2
hours after LPS stimulation preceding detection of IL-6 in
the supernatant. The requirement for transcription in
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Figure 3 JAK2 is phosphorylated and associates with TNFR1 in response to TNFα treatment. TNFα receptor (TNFR1) was
immunoprecipitated from cell lysates of glia that had been treated with TNFα (5 ng/ml) for 0, 5 or 10 minutes, and western-blotted using a
phospho-JAK2 specific antibody. Incubation of glial cells with TNFα stimulated a rapid association between phosphorylated JAK2 and TNFR1 (A).
TNFα treatment of glial cells also induced phosphorylation of STAT1 at 10 minutes (B). The TNFα-stimulated phosphorylation of JAK2 and STAT1
was attenuated when cells were co-incubated with SAR317461 (C). Representative immunoblots of three separate experiments are shown.
Incubation of glial cells with TNFα (5 ng/ml) stimulated release of IL-6 at 6 h (D, ***P< 0.001; ANOVA; n = 3), an effect that was inhibited when
cells were co-treated with TNFα and TG101209 (D, +++P< 0.001; ANOVA; n = 3). TNFα had no adverse effect on cell viability after 24 h of
treatment (E, *P< 0.05; Student’s t-test for independent means; n = 3).
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driving the LPS-induced IL-6 release is supported by the
demonstration that SAR317461 also inhibited the LPS-
induced up-regulation of IL-6 mRNA.
Other signaling molecules, including NFкB, are acti-
vated downstream of TNFα receptor activation [25-27].
NFкB activation is also known to affect IL-6 production/
release in response to LPS treatment. Inhibition of
JAK2/STAT1 exerted no effect on the NFκB signaling
complex, although it inhibited LPS-induced IL-6 pro-
duction. Crosstalk between NFκB and JAK/STAT signal-
ing pathways has been reported [28-30], and it is
therefore possible that NFкB-associated modulation of
IL-6 release reported in the literature may occur as a re-
sult of this crosstalk rather than as a direct effect of in-
hibition of NFκB-dependent gene transcription.
Both transcription of TNFα and its release were up-
regulated in LPS-stimulated glial cells. Inhibition of
JAK2 modestly attenuated the LPS-induced release of
TNFα, contrasting with its ability to completely block
the LPS-induced release of IL-6. However, the mechan-
ism underlying TNFα release differs from that of IL-6.
Translocation of TNFα to the membrane is required.
Here it must undergo a cleavage event prior to release
[31] and, consequently, TNFα release may be modulated
by regulating processing enzymes, up-regulating tran-
scription or release of upstream pro/anti-inflammatory
mediators.
Activation of JAK2/STAT1 is generally observed
within 15 minutes of receptor stimulation [32]. A some-
what delayed LPS-induced response was observed here,
indicating that activation of JAK2 occurs downstream of
signaling kinases or secondary to LPS-induced release of
other cytokines. IL-6 and IL-12 are examples of cyto-
kines which activate JAK2 [13,14], but JAK2 activation
SOCS3
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Figure 4 IL-6 modulates the LPS-stimulated release of IL-1β from glia. Glial cells were treated with LPS)(100 ng/ml) in the presence or
absence of rat recombinant IL-6 (20 ng/ml) and cytokine concentrations were assessed at 24 h (A,C) and SOCS3 expression was examined at 90
minutes (B). The LPS-induced release of IL-1β (A; ***P< 0.001; ANOVA) was partially inhibited when cells were co-incubated with recombinant IL-6
(A; +P< 0.05; ANOVA). SOCS3 expression was induced in the presence of LPS (B) and further enhanced when cells were co-treated with LPS and
recombinant IL-6 (B). IL-10 production was stimulated by LPS treatment (C; ***P< 0.001; ANOVA), an effect that was greater when cells were
stimulated with LPS in the presence of recombinant IL-6 (C; +P< 0.05; ANOVA). Furthermore, inhibition of IL-6 signaling using a neutralizing
antibody to the IL-6 receptor (IL-6R) exacerbated the LPS-induced effect on IL-1β release (D; ++P< 0.01; ANOVA) compared to the IgG istoype
control antibody while inhibiting the LPS-stimulated release of IL-10 (E; +P< 0.05; ANOVA). Similarly, when the LPS-stimulated production of IL-6
was inhibited using siRNA targeted against IL-6 (G; +++P< 0.001; ANOVA), the LPS-induced release of IL-1β was enhanced (F; +P< 0.05; ANOVA),
effects that were not apparent in cells that were incubated in the presence of LPS and the non-target (NT) siRNA (F,G).
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preceded LPS-induced release of both of these cytokines
from glia. In contrast, TNFα release roughly coincided
with the activation of JAK/STAT signaling. While
TNFR1 does not contain any intrinsic tyrosine kinase ac-
tivity, TNFα is known to stimulate tyrosine phosphoryl-
ation [33-37] and here we show that treatment of glia
with TNFα induced an association of phosphorylated
JAK2 with TNFR1. A similar association between JAK2
and the receptor has been reported in HEK293, H1299
lung adenocarcinoma and MCF7 human breast carcin-
oma cells [38]. However, to our knowledge, no such ob-
servation has been made in cells from the CNS. In the
present study, the TNFα-induced association of activated
JAK2 and TNFR1 led to STAT1 phosphorylation and re-
lease of IL-6; SAR317461 prevented both of these
changes. SAR317461 had no effect on phosphorylated
IкBα, ruling out any role for NFкB. Interestingly a
TNFR1 deficiency has a protective effect on myocardial
tissue and decreases myocardial IL-6 concentrations
[39], an observation attributed to enhanced SOCS3 and
decreased STAT3 activation.
LPS-induced release of IL-6 from glia occurs later than
that of TNFα and IL-1β. IL-6 exerts pro- and anti-
inflammatory effects within the CNS [16-19,40-44]. In
the absence of SOCS3, IL-6 inhibits the LPS-stimulated
up-regulation of IL-1β mRNA as well as the release of
TNFα and IL-12 p40 from macrophages [45]. Interest-
ingly, LPS-induced up-regulation of SOCS3 in macro-
phages was enhanced by IL-6. This result indicates an
inhibitory effect of LPS/IL-6 co-treatment on JAK/STAT
signaling, and may explain the partial attenuation of IL-
1β release observed when cells were co-incubated with
LPS and recombinant IL-6. Conversely, the LPS-induced
release of IL-1β was enhanced when IL-6 release was
inhibited with siRNA targeted against the IL-6 gene or
when the interaction between IL-6 and its receptor was
disrupted by an IL-6R monoclonal antibody. However,
we show that incubation of cells in the presence of IL-6
for 24 h also increases the anti-inflammatory cytokine,
IL-10; this, like SOCS3, plays a role in modulating IL-1β
release from several cells including microglia [46]. The
findings indicate that LPS induces production and re-
lease of TNFα which leads to activation of TNFR1 and
the association between this receptor and JAK2. The
subsequent phosphorylation of JAK2 triggers STAT1 ac-
tivation and increased production and release of IL-6
(Figure 5). We propose that two of the events that occur
as a result of increased IL-6 are up-regulation of SOCS3
and production of IL-10, both of which contribute to the
longer term modulation of IL-1β production. Whether
the proposed cascade of events is occurring in one spe-
cific cell type is unclear. LPS-induced activation of JAK/
STAT and the release of IL-6 was apparent in both iso-
lated astrocytes and microglia, an effect that could be
modulated by SAR317461 (data not shown). The subse-
quent effects of modulating IL-6 signaling were not
investigated in isolated cell types since it is uncertain
whether astrocytes express the IL-6 receptor or require
a soluble form to be released to confer IL-6 responsive-
ness [10].
Neuroinflammation has been identified as a key process
in driving the pathogenesis associated with a number of
neurodegenerative conditions such as Alzheimer’s disease,
multiple sclerosis, Parkinson’s disease and brain injury.
Microglia and astrocytes are pivotal in driving this process
since they release inflammatory mediators. Therefore,
strategies which target specific components of the path-
ways leading to release are likely to be important in unco-
vering the sequence of events underlying the pathogenesis
of these diseases. Data from this study identify a key regu-
latory role for JAK2/STAT1 signaling in the production
and release of IL-6 from glial cells, and highlight the com-
plex interactions which govern time-related responses to
LPS.
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Figure 5 Schematic representation of LPS-induced signaling
and cytokine release. Toll-like receptor (TLR)4 is stimulated by LPS
and triggers activation of MAPKs and NFkB (1) which results in
release of TNFα and IL-1β (2). Released TNFα interacts with its
receptor (3), activating JAK2 and STAT1 (4) which up-regulates
transcription and release of IL-6 (5). IL-6 feeds back to inhibit further
release of TNFα and IL-1β (6), limiting the inflammatory changes.
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